Dataset related to article "prognostic factors and outocome in HER2 + in breast cancer with CNS metastases "

this record contains data related to article "prognostic factors and outocome in HER2 + in breast cancer with CNS metastases " Aim: Trastuzumab prolongs progression-free and overall surviva l in HER2+ breast cancer (BC), but these are associateci with increased distant recurrences and centrainervous system metastases (CNSm). We retro­ spectively evaluated outcome and prognostic factors in CNSm and non-CNSm patients. Methods: Records of HER2+ BC treated in 2000-2017 were reviewed.Results: 283/1171 (24%) HER2+ BC patients developed metastatic disease. 109/283 patients (39%) have CNSm associateci with worse prognosis and increased risk of death (hazard ratio: 4.7;95% Cl: 3.5-6.4). Prognostic factors were: number of CNSm (single vs multi­ ple lesions; 3-year overall survival 39 vs 18%; p = 0.003); brain radiation (30 vs 14%; p < 0.001); new HER2-targeting therapies (30.6 vs 22.5%; p = 0.025). Conclusion: Prognosis of BC patients with CNSm has improved using HER2-targeting therapies but remains poor